Whitehawk Therapeutics, Inc. WHWK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -100.43% | 32.81% | -- |
| Gross Profit | -- | -- | 66.79% | -299.69% | -- |
| SG&A Expenses | -12.19% | -50.92% | -46.92% | -27.62% | -24.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -66.92% | 5.18% | -4.97% | 8.67% | 151.57% |
| Operating Income | 66.92% | -54.57% | -31.34% | -81.40% | -251.32% |
| Income Before Tax | 68.37% | -130.40% | -27.24% | -41.45% | -260.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.37% | -130.40% | -27.24% | -41.45% | -260.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.37% | -130.40% | -27.24% | -41.45% | -260.80% |
| EBIT | 66.92% | -54.57% | -31.34% | -81.40% | -251.32% |
| EBITDA | 66.92% | -55.14% | -31.66% | -82.15% | -252.32% |
| EPS Basic | 73.63% | -117.41% | 50.21% | 44.74% | -41.06% |
| Normalized Basic EPS | 73.63% | 11.96% | 50.19% | 30.70% | -41.08% |
| EPS Diluted | 73.63% | -117.52% | 50.32% | 43.97% | -41.04% |
| Normalized Diluted EPS | 73.63% | 11.29% | 50.19% | 30.70% | -41.08% |
| Average Basic Shares Outstanding | 19.98% | 74.66% | 155.52% | 155.92% | 155.77% |
| Average Diluted Shares Outstanding | 19.98% | 73.38% | 155.52% | 155.92% | 155.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |